Abstract
Chronic estrogen deficiency is a major cause of morbidity and mortality among postmenopausal women. The most compelling sequelae are coronary artery disease and osteoporotic fractures, but other effects related to loss of estrogen can seriously impair quality of life[1,2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Honjo H, Tanaka H, Kashiwagi T, et al. Senile dementia—Alzheimer’s type and estrogen. Hormone Metab Res 1995;27:204–7.
Kauffman RF, Bryant HU. Selective estrogen receptor modulators. Drug News and Perspectives 1995;8:531–39.
Compston JE. HRT and osteoporosis. Br Med Bull 1992:48:309–44.
Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995;273:199–208.
Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589–93.
Hammond CB. Women’s concerns with hormone replacement therapy—compliance issues. Fertil Steril 1994;62(Suppl 2):157S–160S.
Data on file, Lilly Research Laboratories.
Draper MW, Flowers DE, Huster WJ, Neild JA, Harper D, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11:835–42.
Morii H, Orimo M, Takani Y, et al. Effect of raloxifene hydrochloride on postmenopausal Japanese women with osteoporosis. J Bone Miner Res 1996;11(Suppl 1):S446 (abstr T588).
Manson JE. Postmenopausal hormone therapy and atherosclerotic disease. Am Heart J 1994; 128:1337–43.
Fuchs-Young R, Glasebrook AL, Short LL, et al. Raloxifene is a tissue selective agonist/ antagonist that functions through the estrogen receptor. Ann NY Acad Sci 1995;761:355–60.
Kleinman D, Karas M, Danilenko M, et al. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-1 induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 1996;137:1089–95.
Anzano MA, Peer CW, Smith JM, et al. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996;88:123–25.
Yang NN, Venugopalan M, Hardikar S, Glasebrook A, et al: Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996;273: 1222–25.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Termine, J.D. (1997). Raloxifene HCl: A Tissue Selective Estrogen Receptor Modifier (SERM) for Replacement Therapy in Postmenopausal Women. In: Paoletti, R., Crosignani, P.G., Kenemans, P., Samsioe, G., Soma, M.R., Jackson, A.S. (eds) Women’s Health and Menopause. Medical Science Symposia Series, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5560-1_45
Download citation
DOI: https://doi.org/10.1007/978-94-011-5560-1_45
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6343-2
Online ISBN: 978-94-011-5560-1
eBook Packages: Springer Book Archive